Liquidia wins against United Therapeutics in patent battle over PAH drug

2024-04-01

申请上市专利侵权

United Therapeutics has suffered two court losses in its fight to keep a competitor for its blockbuster drug Tyvaso (treprostinil) from entering the market, with federal judges ruling in favor of Liquidia and the FDA in separate cases last week. Liquidia announced Monday that a federal judge in Delaware got rid of a 2022 injunction that was part of a patent lawsuit brought by United Therapeutics, finally allowing the FDA to approve Liquidia’s NDA for Yutrepia, its version of treprostinil, an inhaled powder that treats pulmonary arterial hypertension (PAH). With approval, Liquidia would be entering a blockbuster market: United said in its latest earnings that Tyvaso brought in $1.2 billion in sales in 2023, a 41% increase over the previous year.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Liquidia Corp.